Apixaban

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Anticoagulation

Conditions

Anticoagulation

Trial Timeline

Mar 24, 2015 → Jun 4, 2018

NCT ID

NCT01884337

About Apixaban

Apixaban is a approved stage product being developed by Pfizer for Anticoagulation. The current trial status is completed. This product is registered under clinical trial identifier NCT01884337. Target conditions include Anticoagulation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04681482	Pre-clinical	Completed	Nov 2, 2020	Nov 3, 2020	Atrial Fibrillation
NCT03590743	Approved	Terminated	Feb 19, 2019	Jun 3, 2019	Deep Vein Thrombosis
NCT02369653	Phase 3	Completed	Oct 22, 2015	Jul 7, 2021	Lymphoma
NCT01884337	Approved	Completed	Mar 24, 2015	Jun 4, 2018	Anticoagulation
NCT01707394	Phase 1	Completed	Jan 10, 2013	Jun 30, 2020	Thromboembolism
NCT02034591	Phase 1	Completed	Oct 1, 2011	Nov 1, 2011	Healthy Subjects
NCT01195727	Phase 1	Terminated	Jul 26, 2011	Jul 16, 2012	Venous Thromboembolism
NCT02034578	Phase 1	Completed	Jul 1, 2011	Aug 1, 2011	Healthy Volunteers
NCT02034565	Phase 1	Completed	Feb 1, 2010	Mar 1, 2010	Healthy Volunteers

Competing Products

7 competing products in Anticoagulation

See all competitors

Product	Company	Stage	Hype Score
VKA + Apixaban + dabigatran + rivaroxaban	Bristol Myers Squibb	Pre-clinical	22
Apixaban	Bristol Myers Squibb	Pre-clinical	22
Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution)	Bristol Myers Squibb	Phase 1	32
four factor prothrombin complex concentrate	CSL	Approved	84
DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin)	Bayer	Pre-clinical	20
Prismocitrate 18	Baxter	Phase 3	74
Prismocitrate 18	Baxter	Phase 3	74

Other Products from Pfizer